Interprotein®

Helix-loop-helix peptide NKG2A inhibitor

Concept:

- We identify injectable helix-loop-helix NKG2A inhibitor as an immune checkpoint inhibitor of the next generation.
- Such peptide can be alternatives to anti-NKG2A antibody drugs and is expected to be more easily used beyond antibody-treated segments.

Research history:



Present status and future scope:

1. We started a new program for identification of helix-loop-helix peptides (HLHPs) that bind to NKG2A, one of immune checkpoints of the next generation, from phage libraries and yeast display libraries by a biopanning method and a flow cytometric screening system, respectively.

2. HLHP clones that bind to NKG2A with K_D values of less than 1 µmol/L have been identified, and the best value is 38 nmol/L.

3. We are seeking for a collaborative research partner that would conduct *in-vitro* functional assay, *in-vivo* efficacy assessment and so on.